Traditional RNA sequencing methods often struggle to capture the nuances of trans-splicing—an RNA processing event where exons from different pre-mRNA molecules are joined together. This unique form of splicing has been relatively underexplored, largely due to technical limitations in distinguishing trans-spliced variants from the more common cis-spliced transcripts. The innovation presented in this protocol addresses these challenges head-on by incorporating enhanced molecular tagging and amplification strategies to faithfully preserve the native architecture of trans-spliced mRNAs.

The power of single-cell sequencing lies in its ability to discern cellular heterogeneity that bulk sequencing methods average out. By applying this resolution to trans-splicing events, the new protocol enables researchers to map how individual cells harness this process to diversify their transcriptomes. This can reveal regulatory layers previously masked in population-level analyses, providing clues about cell type-specific functions, developmental trajectories, and responses to environmental stimuli.

Central to the protocol’s success is its meticulous capture of the transcript’s 5’ and 3’ ends, allowing unambiguous identification of trans-spliced junctions. The approach leverages novel enzymatic reactions and ligation steps carefully optimized to maintain sequence integrity, enabling high-fidelity reconstruction of splicing landscapes. Moreover, the method integrates seamlessly with established single-cell RNA sequencing platforms, widening accessibility and potential for widespread adoption.

The practical implications of this development are vast. Researchers can now probe the role of trans-splicing in normal physiology and pathogenesis with precision. Given that aberrant RNA splicing is implicated in various cancers and genetic disorders, understanding trans-splicing patterns at the single-cell level could illuminate new biomarkers and therapeutic targets. Furthermore, tissues with complex cell compositions, such as the brain or immune system, stand to benefit profoundly from this refined analytical lens.

Implementing this protocol requires meticulous experimental execution. Steps include cell isolation, mRNA extraction under conditions preserving RNA integrity, strategic reverse transcription with specialized primers, as well as a series of purification and amplification cycles designed to enrich for trans-spliced sequences. Each phase has been rigorously characterized to maximize sensitivity and specificity, ensuring reproducible outcomes across diverse sample types.

Bioinformatic analysis pipelines accompanying the protocol are equally sophisticated. They employ advanced algorithms capable of distinguishing genuine trans-splicing events from experimental artifacts or sequencing errors. These computational tools facilitate high-confidence annotation of transcripts, visualization of splicing diversity, and quantification of junction abundance at single-cell resolution, pushing the analytical frontier forward.

Beyond capturing static snapshots, the technology opens pathways to dynamic studies. Scientists can track how trans-splicing activity varies during cellular differentiation, in response to external cues, or throughout disease progression. This temporal dimension adds a vital layer of understanding to RNA biology’s functional repertoire, potentially revealing regulatory checkpoints amenable to therapeutic modulation.

The introduction of this high-resolution sequencing method also underscores the increasing convergence of experimental and computational biology. It reflects a growing recognition that unraveling complex molecular phenomena demands integrated approaches combining cutting-edge laboratory techniques with robust data science. This synergy not only accelerates discovery but democratizes access to intricate biological insights.

Intriguingly, this approach may shed light on evolutionary aspects of splicing. Differences in trans-splicing prevalence and patterns across species and cell types could inform hypotheses about RNA processing’s adaptive significance. Delineating these evolutionary narratives may provide broader context for interpreting functional data and guiding synthetic biology applications.

Moreover, the methodology’s adaptability hints at future expansions. For example, coupling this protocol with spatial transcriptomics could map trans-spliced mRNAs within tissue architecture, or integrating with proteomics could link transcript variants to protein isoform expression. Such multidimensional analyses hold promise for unraveling the intricate web connecting genotype to phenotype.

As research workflows adopt this technology, anticipated challenges include managing increased data complexity and scaling up throughput for large single-cell atlases. Nonetheless, the benefits—unveiling the hidden layers of transcriptomic regulation with unprecedented clarity—far outweigh these hurdles. The authors’ thorough validation in diverse biological contexts allays concerns about adaptability and robustness.

Ultimately, this state-of-the-art protocol propels trans-splicing research to new heights, furnishing the scientific community with a versatile toolset to decode RNA’s role in health and disease at unparalleled resolution. It exemplifies a milestone where technological ingenuity meets biological inquiry, heralding a new era in transcriptomic sciences.

As this methodology gains traction, it is poised to catalyze transformative discoveries, deepen our molecular understanding, and inspire follow-up innovations. The potential ripple effects extend from basic science to clinical diagnostics, underlining the enduring impact of pioneering single-cell approaches in unlocking cellular complexity comprehensively.

Subject of Research: High-resolution single-cell sequencing of trans-spliced mRNA

Article Title: High-resolution single-cell sequencing of trans-spliced mRNA

Article References:
Cosentino, R.O., Keneskhanova, Z., Esser, S. et al. High-resolution single-cell sequencing of trans-spliced mRNA. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01373-7

DOI: https://doi.org/10.1038/s41596-026-01373-7

Image Credits: AI Generated

Tumors are no longer viewed as mere clusters of malignant cells but as complex ecosystems. The intricate interplay between cancer cells, immune cells, fibroblasts, and surrounding extracellular matrix (ECM) literally shapes disease progression and treatment responses. While traditional pathology protocols offered two-dimensional snapshots often limited to histological staining, this research leverages high-resolution single-cell spatial technologies, offering a multidimensional and molecularly precise view of tumor architecture with cellular neighborhood resolution.

Central to this advancement is the application of spatial transcriptomics, a technology that profiles RNA expression with remarkable spatial context. Unlike conventional transcriptomics, which bulk-analyzes RNA from homogenized tissue samples, spatial transcriptomics preserves the positional information of transcripts at single-cell resolution. Employing the innovative CosMx platform by NanoString, Rajewsky’s team was able to detect up to 1,000 distinct RNA molecules per cell, a quantum leap from earlier methods constrained to just a few markers. This enabled detailed profiling of over 340,000 individual cells, encompassing 18 distinct cell types within a single lung tumor, highlighting the heterogeneous cellular milieu.

However, the leap from two-dimensional to three-dimensional analysis required innovative computational solutions. The team introduced STIM, a novel algorithm designed to reconstruct 3D virtual tissue blocks by aligning multiple spatial transcriptomic datasets. STIM conceptualizes spatial transcriptomic data as digital images, applying computer vision techniques to stack and align these images, culminating in a holistic 3D tissue reconstruction. This integration underscores the power of interdisciplinary collaboration, merging computational sciences with molecular biology, and was further enhanced by expertise from Dr. Stephan Preibisch at the Howard Hughes Medical Institute.

The 3D reconstructions revealed more than just cellular identities: by coupling these maps with second harmonic generation imaging, the researchers visualized key ECM components, including elastin and collagen fibers. This dual-layered imaging disclosed spatial variations in ECM composition, where elastin-rich regions correlated with healthier tissue, whereas areas rich in collagen congregated around the tumor core, signifying deleterious tissue remodeling driven by the tumor microenvironment. Such details illuminate how structural alterations to the ECM contribute to cancer progression.

Crucially, this approach illuminated dynamic cellular interactions within the tumor. Fibroblasts, cells responsible for synthesizing connective tissue, were observed in activated states remodeling the ECM, creating a scaffold supporting tumor growth. Beyond static snapshots, the data unveiled functional phenotypes and intercellular signaling, particularly mechanisms by which tumor cells suppress infiltration of immune cells. The findings emphasized the presence of immune niches surrounding the tumor core that, despite their proximity, were functionally impaired due to tumor-induced immunosuppression.

Understanding the precise molecular crosstalk that underpins immune evasion is vital. The study exposes how tumors can inhibit immune cell penetration through known checkpoint pathways, validating immunotherapy strategies that employ immune checkpoint inhibitors. By reversing this localized immune suppression, such therapies could unleash resident immune cells that are otherwise incapacitated, offering a personalized treatment strategy that conventional chemotherapy alone could not provide.

What sets this research apart is its applicability to routine clinical samples. Despite utilizing sophisticated molecular techniques, the team demonstrated that archived formalin-fixed, paraffin-embedded (FFPE) tissue sections—commonly preserved in clinical pathology labs—are amenable to this high-resolution analysis. This “Pathology 2.0” approach transcends traditional microscopy, enriching pathological examination with molecular and spatial depth, and has the potential to transform diagnostic and therapeutic decision-making in oncology.

The translational promise of this integrated spatial approach is monumental. By comprehensively mapping cellular neighborhoods and molecular signals within tumors, physicians could tailor immunotherapies and other interventions with unprecedented precision. Moreover, expanding these techniques to larger patient cohorts is underway, with ongoing analyses involving hundreds of additional samples. Such scaling will enable validation of molecular targets and foster development of broadly applicable personalized medicine protocols.

Another frontier being explored involves integrating proteomic data into the comprehensive tissue map. Collaborations with Dr. Fabian Coscia’s Spatial Proteomics Lab at MDC aim to incorporate protein activity measurements alongside RNA expression and ECM imaging. This multi-omic synergy will deepen insights into functional tumor biology, elucidate post-transcriptional regulation, and refine therapeutic target identification.

This study represents a paradigm shift in cancer research and diagnostics. By synergizing single-cell resolution spatial transcriptomics with advanced ECM imaging and novel computational reconstructions, researchers can now dissect the tumor microenvironment with molecular and spatial fidelity previously unattainable. The resulting data describe not only who is present in the tumor but where, how, and why they interact – all essential information for designing personalized therapies capable of halting tumor progression and improving patient outcomes.

Professor Rajewsky encapsulates the significance succinctly: the comprehensive data from patient tumor tissues now allow computational predictions of the molecular mechanisms driving cancer phenotypes. This predictive capacity could revolutionize oncology, moving from generalized treatments toward truly individualized interventions—a vision for precision medicine now within reach.

In essence, the collaboration between biology, computational science, and advanced imaging heralds a new era where high-tech analytical tools refine routine pathology into a powerful platform for personalized cancer care. The integration of spatial, molecular, and functional data sets a foundation for next-generation diagnostics and therapeutics, promising hope for patients facing lung cancer and other malignancies. With further validation and clinical application, these innovations will likely redefine cancer management strategies over the coming decade.

—

Subject of Research: Cells

Article Title: Combining spatial transcriptomics and ECM imaging in 3D for mapping cellular interactions in the tumor microenvironment

News Publication Date: 11-Apr-2025

Web References: 10.1016/j.cels.2025.101261

Image Credits: Rajewsky lab, Max Delbrück Center

Keywords: spatial transcriptomics, 3D tumor mapping, extracellular matrix imaging, single-cell analysis, lung cancer, tumor microenvironment, immunotherapy, computational modeling, personalized medicine